In December 2019, a novel coronavirus, currently defined as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was identified as the aetiological agent of a *cluster of pneumonia* in Wuhan, China \[[@keaa194-B1]\]. Since this outbreak, the novel coronavirus disease (COVID-19) has spread worldwide. By 30 March 2020, COVID-19 had reached pandemic proportions, involving \>110 countries and \>600 000 cases \[[@keaa194-B2]\]. Most cases of COVID-19 are self-limiting, but up to 20% of infected patients show a severe or critical disease, including severe pneumonia and multi-organ failure \[[@keaa194-B3]\]. Systemic immune abnormalities feature in severe COVID-19. Despite peripheral blood showing a reduced lymphocyte number, there is a hyperactivation state of T cells, with an increase of Th17 and a high cytotoxic activity of CD8 \[[@keaa194-B4]\]. Moreover, patients with severe COVID-19 show increased serum IL-6 levels and reduced number of circulating NK cells. Globally, these clinical and serological abnormalities characterize a cytokine release syndrome (CRS) \[[@keaa194-B5]\]. During CRS, the systemic activation of immune cells causes the release of a large quantity of cytokines with the aim of limiting viral diffusion and clearing the infection. However, uncontrolled immune system activation can cause terminal organ damage, evolving towards multi-organ failure \[[@keaa194-B6]\].

So far, there is no available specific antiviral treatment for COVID-19, and management is largely supportive. However, in light of the increasing understanding of SARS-CoV-2 biology and COVID-19 pathophysiology, several drugs commonly used in rheumatology have been proposed as potential COVID-19 treatments ([Fig. 1](#keaa194-F1){ref-type="fig"}).
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Chloroquine (CQ) and hydroxychloroquine (HCQ) are antimalarial agents with immune-modulatory activities largely used in rheumatology. These agents present also a well-known antiviral activity, involving a broad spectrum of viral species \[[@keaa194-B7]\]. The drugs act by increasing endosomal pH and inhibiting toll-like receptors, interfering with virus--cell fusion, as well as interfering with the glycosylation of angiotensin-converting enzyme 2 (ACE2), which represents the cellular receptor of the virus \[[@keaa194-B8]\]. *In vitro* studies demonstrated an antiviral activity against SARS-COV-2 at concentrations achievable at the usual therapeutic doses. Moreover, the immune-modulatory activity of these agents, limiting the systemic immune activation associated to COVID-19, could act synergistically to the antiviral properties \[[@keaa194-B9]\]. Several clinical trials conducted in China demonstrated superiority of CQ treatment with respect to placebo in improving the evolution of COVID-19 pneumonia and promoting viral clearance \[[@keaa194-B10]\]. Accordingly, several medical agencies, including Chinese and Italian ones, included CQ and HCQ in the recommendations for treatment of COVID-19 \[[@keaa194-B11], [@keaa194-B12]\]. Recently, a small non-randomized trial evaluating the combination of HCQ and azithromycin in 36 SARS-CoV-2 positive subjects showed a significant efficacy of the combination in clearing the viral nasopharyngeal carriage compared with the control treatment \[[@keaa194-B13]\]. Azithromycin activates antiviral interferon pathways in bronchial epithelial cells, suggesting an additive effect to its antimalarial action and a potential utility against viral spread \[[@keaa194-B14]\]. Moreover, HCQ shows a higher antiviral activity compared with CQ on *in vitro* SARS-CoV-2 infected cells \[[@keaa194-B15]\]. However, the small size and the non-randomized design limit the strength of the studies. Larger randomized clinical trials (RCT) investigating HCQ efficacy, with or without azithromycin, in COVID-19 patients as well as prophylactic treatment in healthcare providers have been announced in several countries, including Australia, Brazil (NCT04321278), Denmark (NCT04322396) and Spain (NCT04304053).

The development of a CRS has a pivotal role in severe COVID-19. The persistent viral stimulation leads to a significant increase of circulating cytokines such as IL-6 and TNFα, which are negatively related to the absolute lymphocyte count and can trigger inflammatory organ damage \[[@keaa194-B16]\]. IL-6 is central in the pathogenesis of CRS associated to SARS-CoV-2 and consequently tocilizumab, a humanized anti-IL-6 receptor (IL-6R) monoclonal antibody, gained interest as a potential treatment of COVID-19. A retrospective study on 21 patients affected by severe COVID-19 showed that tocilizumab treatment improved the clinical manifestations in most of the patients \[[@keaa194-B17]\]. Despite the fact that RCTs investigating the safety and the efficacy of tocilizumab in COVID-19 are still ongoing (ChiCTR2000029765; NCT04317092), both Chinese and Italian recommendations led to tocilizumab being introduced as an option for patients with extensive and bilateral lung disease or severely ill patients with elevated IL-6 levels \[[@keaa194-B11], [@keaa194-B12]\]. Similarly, sarilumab, a fully human anti-IL6R antibody, is currently under investigation in severe COVID-19 (NCT04315298).

SARS-CoV-2 shares several similarities with SARS-CoV, the coronavirus strain responsible for the 2002 SARS pandemic. Both viruses use the spike (S)-proteins to engage their cellular receptor, ACE2, for cell invasion \[[@keaa194-B18]\]. ACE2 expression is upregulated by both SARS-CoV-2 infection and inflammatory cytokine stimulation \[[@keaa194-B19]\]. In SARS-CoV infection, S-proteins can induce shedding of the ectodomain of ACE2, a process strictly coupled to TNFα production \[[@keaa194-B20]\]. This loss of ACE2 activity caused by shedding has been associated to lung injury as a consequence of an increased activity of the renin--angiotensin system \[[@keaa194-B21]\]. Although mainly demonstrated for SARS-CoV, the homology between the structures of S-proteins suggests that also SARS-CoV-2 S-proteins may show a similar mechanism \[[@keaa194-B22]\]. The increased TNFα production could consequently both facilitate viral infection and cause organ damage. Indeed, anti-TNFα treatment has been suggested as a possible treatment option in COVID-19 \[[@keaa194-B23]\], and a RCT investigating adalimumab in COVID-19 has recently been registered (ChiCTR2000030089).

Clathrin-dependent endocytosis is crucial for viral invasion of pneumocytes \[[@keaa194-B24]\]. This process is promoted by members of the numb-associated kinase (NAK) family, which have been proposed as targets to limit intracellular viral traffic. Tyrosine kinase inhibitors, targeting NAK family members, showed good antiviral activity *in vitro* \[[@keaa194-B25]\]. JAK inhibitors, including baricitinib, ruxolitinib and fedratinib, show the ability to inhibit NAK, limiting also systemic inflammatory response and cytokine production through the inhibition of the canonical JAK--STAT pathway \[[@keaa194-B26]\]. Among these, baricitinib is the only JAK inhibitor to reach, at therapeutic and well-tolerated doses, plasmatic concentrations sufficient to inhibit NAK members \[[@keaa194-B27]\]. A RCT investigating baricitinib efficacy in COVID-19 is currently ongoing (NCT04320277).

Severe COVID-19 represents the first example of an infectious disease successfully treatable with immune-modulating therapies. While the ongoing outbreak of COVID-19 requires the urgent development of a vaccine, this unexpected indication for anti-rheumatic therapies underlines the need to better understand how infectious agents trigger the immune system to produce severe clinical manifestations, especially in the case of pandemics.
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